PRESCIENT LTD ORDINARY (PTX) Short Interest
PRESCIENT LTD ORDINARY (ASX:PTX) had 0.00% of shares reported as short positions as of 20 June 2026, representing 10,996 shares. PRESCIENT LTD ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
PTX
Prescient Therapeutics
Prescient Therapeutics is a clinical-stage oncology company focused on developing targeted therapies for cancer treatment. Their business model centers around advancing a diversified pipeline of assets, including PTX-100 in Phase 2a clinical development, and next-generation cell therapy platforms like OmniCAR and CellPryme, sourced from collaborations with leading research institutions.